echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > After the failure of the last healthcare negotiation, these five varieties seized the opportunity

    After the failure of the last healthcare negotiation, these five varieties seized the opportunity

    • Last Update: 2019-11-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In 2019, the results of health insurance negotiation have been announced A total of 97 drugs have been successfully negotiated and payment standards have been determined, including 70 varieties that have been successfully negotiated for the first time and 27 varieties that have been negotiated for renewal Among the successful varieties in this negotiation, we also selected and focused on five of the more special varieties, that is, the varieties that experienced a failure in the 2017 health insurance negotiation As you know, in 2017, 44 varieties were listed in the medical insurance negotiation, 36 of which were successful, 8 of which were failed, and the specific reason is unknown In 2018, the state health insurance bureau organized a special negotiation on anticancer drugs The failed cetuximab injection was entered into the special negotiation, with the price of 1295 yuan As it is still in the agreement period, it did not participate in the renewal negotiation According to the results of this announcement, we found that five of the remaining seven negotiated varieties were finally listed in the national health insurance category B, including bosentan tablets, Xuebijing injection, urinary kallidinogenase for injection, Yiqi Fumai for injection and infliximab for injection Eight varieties that failed in a medical insurance negotiation Bosentan tablets were developed by Switzerland's actelon company In 2001, the US FDA approved it for the treatment of pulmonary hypertension In 2006, bosentan tablets entered the Chinese market At that time, the price was about 27000 yuan / box In 2010, the price was adjusted to 19980 yuan / box In October 2015, bosentan's patent expired In response to the impact of generic drugs, from January 1, 2016, the price decreased from 19980 yuan / box to 3998 yuan / box (specification: 125mg * 56 pieces / box), with a price reduction of 80% Before entering the medical insurance this time, the drug was paid by all patients at their own expense According to its maintenance dose of 125 mg, calculated twice a day, the annual drug burden of patients before entering the medical insurance is 52000 yuan Bosentan is a specific and competitive double endothelin receptor antagonist, which can reduce pulmonary and systemic vascular resistance, increase cardiac output without increasing heart rate, and improve the exercise ability and hemodynamic indexes of patients with idiopathic pulmonary hypertension (PAH) Pulmonary hypertension is a chronic, life-threatening, malignant and rare disease caused by arterial hypertension between the heart and lung Patients have no special symptoms in the early stage, so they are easy to be misdiagnosed and missed diagnosis In the era of traditional drug treatment, the survival time of patients is only 2.8 years, and the death rate is similar to that of cancer It is reported that the incidence rate of pulmonary hypertension in China is 1 to 2/100 million, which is a rare disease However, the incidence of pulmonary hypertension has been increasing gradually in recent years On October 9 this year, the national health and Health Commission and others issued the catalogue of the first batch of drugs to be encouraged to imitate, among which traprostanil injection and bosentan tablet, two drugs for the treatment of pulmonary hypertension, were listed At present, the domestic enterprises that have been imitated include Zhejiang Pharmaceutical, Zhejiang Huayi pharmaceutical, Jiangsu Yabang Johnson & Johnson pharmaceutical, Chongqing shenghuaxi pharmaceutical, Chongqing Huabang, Yuanda pharmaceutical, etc., all of which have been approved for clinical application The success rate of the second negotiation should be higher for the varieties that have experienced the first negotiation After all, I have learned more about the expectation of the medical insurance bureau and the actual situation of the negotiation with the medical insurance bureau In addition, after two years of negotiation, enterprises will have a clearer understanding of industry policy orientation and market competition than before For example, the external environment of Xuebijing injection and infliximab for injection in the above table has changed greatly compared with that two years ago.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.